Skip to main content
. 2016 Aug 4;7(35):56699–56712. doi: 10.18632/oncotarget.11057

Figure 4. Dual knockdown of the YAP/TAZ co-activators in HCT116 and RKO cells is associated with cellular quiescence and decreased Cyclin E1 levels.

Figure 4

(A) Expression of YAP, P-YAP (Ser127), TAZ, Cyr61 and AXL analyzed by Western blotting. B- TEAD relative activity in control cells (HT29, 5F31, HCT116, RKO) and VP-treated HCT116 cells (2.5 and 5 μM VP). (B, C) Impact of VP treatment on TEAD activity and Cyclin E1 and c-Myc levels in HCT116 cells. (D) Percentage of G0 cells in YAP-, TAZ- and YAP/TAZ-silenced HCT116 and RKO cells. Cells were treated by 15 nM YAP siRNA and/or 15 nM TAZ siRNA and processed for the quantification of G0 phase cells by flow cytometry using Ki-67 labelling. Control cells are transfected with non-targeting sequence. Data are from 3 replicates. (E) Effect of YAP-, TAZ- and YAP/TAZ-silencing on Cyclin E1 and c-Myc levels in HCT116 and RKO cells. (F, G) Effect of Cyclin E1 silencing on cellular quiescence in 5F31, HCT116 and RKO cells. Cyclin E1 siRNA concentration was 30 nM for 5F31 cells and 15 nM for HCT116 and RKO cells. Control cells are transfected with nontargeting sequence. Control and silenced cells were then processed for the quantification of G0 phase cells by flow cytometry using Ki-67 labelling. Data are from 3 replicates. Western blots are representative of at least 3 experiments.